Skip to main content

cancer immunotherapy Archives

GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment

Jan. 7, 2019—GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.

Read more


Breast cancer-killing RIG

Dec. 13, 2018—A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.

Read more


Immunotherapies linked to specific heart complications

Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

Read more


Team’s findings show glutamine metabolism affects T cell signaling

Nov. 1, 2018—The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.

Read more


Cancer immunotherapy drugs linked with more serious heart effects

Mar. 12, 2018—Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.

Read more


Recent Stories from VUMC News and Communications Publications

Our amazing skin

Vanderbilt Medicine

Our amazing skin

Biology and the beat

Vanderbilt Medicine

Biology and the beat

Community care

Vanderbilt Nurse

Community care

Survive and thrive

Hope

Survive and thrive

more